Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
325.00    -8.00 (-2.40%)
Bid:
320.00
Ask:
330.00
Spread: 10.00 (3.125%)
Market Cap: £41.24m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Trading Update

18 Jan 2016 07:00

RNS Number : 1012M
BrainJuicer Group PLC
18 January 2016
 

 

 

 

Press Release

18 January 2016

 

 

BrainJuicer Group PLC (AIM: BJU)

("BrainJuicer", "the Company", or "the Group")

 

Pre Close Trading Statement

 

BrainJuicer, the innovative international market research agency, today releases the following update on trading for its financial year ended 31 December 2015. The Company will announce its final results on 21 March 2016.

 

As usual, trading was stronger in the second half of the year than in the first half. For the year as a whole, revenue increased by 2% to approximately £25.2m, and gross profit by 4%. The impact of currency movements on the business as a whole was not material. Among our core markets, the US performed strongly with revenue increasing by approximately 21%. Revenue in the UK declined by 4%. Elsewhere, revenue declined in Continental Europe and in our relatively small Asian and Brazilian businesses.

 

The modest increase in overall revenue masks the encouraging growth delivered by our core quantitative products and services - with growth estimated at 7% for the year. As anticipated the Group's overall growth rate was dampened by the continued decline in revenue from our lower margin, less scalable Juice Generation qualitative research. As highlighted in our Interim Results statement, we have spent the last 18 months replacing the qualitative business with, higher margin, more scalable brand tracking research. Tracking now represents 7% of the business and is expected to continue growing strongly in 2016. Almost all of the company's Juicy products are now higher margin, more scalable quantitative research services which will help to deliver progressively stronger growth.

 

Pre-tax profits for 2015 are expected to be approximately £4.5m (2014: £4.3m) in line with market expectations. Adjusted pre-tax profits, after adding back one-off charges incurred in H1 of £0.3m and share-based payments of £0.2m, are expected to be approximately £5.0m.

 

BrainJuicer has again proved highly cash generative this year. The Company returned £1.5m to shareholders during 2015 via ordinary dividends and management option share buy backs, and ended 2015 with a cash balance of £6.3m, equivalent to 48 pence per share, compared with £5.3m in 2014. BrainJuicer has no debt.

 

Looking ahead, 2016 will be another year of investment in pursuit of sustainable, long-term growth. Notably, we are investing in setting up a creative agency: System1 - Feel More, Buy More. The agency will be distinctive in the market, with no fixed creative department or the overheads of one. In an "Uber-era", there is creative talent available, which System1 will tap by briefing multiple creatives for each client brief. Every idea will be pre-tested using BrainJuicer's methods and only high scoring ideas will be presented to clients. Our small in-house team will be led by a highly experienced industry figure, who has recently joined the company.

 

This and other initiatives should over time help us to build top line momentum after the modest growth of the last 2 years.

 

The Company can be found at www.brainjuicer.com.

 

For further information, please contact:

BrainJuicer Group PLC

Tel: +44 (0)20 7043 1000

 

John Kearon, Chief Executive Officer

 

James Geddes, Chief Financial Officer

 

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

Simon Bridges / Henry Fitzgerald-O'Connor / Emma Gabriel

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUVAWRNUAAAAR
Date   Source Headline
1st May 20264:30 pmRNSHolding(s) in Company
21st Apr 20267:01 amRNSRelationship Agreement with Brave Bison
21st Apr 20267:00 amRNSQ4 and Full Year Trading Update
9th Apr 20267:00 amRNS-RLaunch of next evolution of Test Your Ad platform
30th Mar 20264:30 pmRNSHolding(s) in Company
30th Mar 20263:30 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTrading Update
16th Mar 20267:00 amRNSTrading Update
5th Mar 20263:15 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:15 pmRNSHolding(s) in Company
3rd Mar 20264:06 pmRNSBoard Change
2nd Mar 20261:39 pmRNSShareholder update & PDMR Dealing
2nd Mar 20267:00 amRNSDirectorate change
30th Jan 20261:00 pmRNSBoard Committee and Change of Role Update
20th Jan 20267:00 amRNSTrading Update
12th Jan 20264:45 pmRNSAppointment of Joint Corporate Broker
2nd Dec 20257:00 amRNSInterim Results
20th Nov 202511:45 amRNSHolding(s) in Company
24th Oct 20253:28 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSTrading Update
14th Oct 20259:16 amRNSCapital Markets Day
6th Oct 20253:30 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSDirector/PDMR Shareholding - replacement
29th Sep 20255:48 pmRNSDirector/PDMR Shareholding
29th Sep 20251:27 pmRNSHolding(s) in Company
26th Sep 20252:29 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 20253:01 pmRNSResult of AGM
23rd Sep 20257:00 amRNSTrading Update
15th Sep 20251:00 pmRNSDirector/PDMR Shareholding
27th Aug 20254:51 pmRNSNotice of AGM
8th Aug 20254:35 pmRNSDirector/PDMR Shareholding
9th Jul 20257:00 amRNSDirector Role Change
9th Jul 20257:00 amRNSFinal Results
9th Jul 20257:00 amRNSTrading Update
4th Jul 202511:45 amRNSHolding(s) in Company
4th Jul 20257:00 amRNSHolding(s) in Company
16th Jun 20251:30 pmRNSHolding(s) in Company
14th May 20257:00 amRNSEstablishment of New Long-Term Incentive Plan
24th Apr 20251:53 pmRNSHolding(s) in Company
23rd Apr 20257:00 amRNSTrading Statement
23rd Jan 20257:00 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTrading Update
8th Jan 202510:15 amRNSHolding(s) in Company
3rd Dec 20247:00 amRNSInterim Results
28th Nov 20247:00 amRNSInterim Results Presentation
21st Nov 20243:31 pmRNSHolding(s) in Company
28th Oct 202410:15 amRNSDirector/PDMR Shareholding
23rd Oct 20247:00 amRNSDirector/PDMR Shareholding
22nd Oct 20247:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.